As shown in Figure 1B, FDX1 was upregulated in Bladder Urothelial Carcinoma (BLCA), BRCA, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), COAD, esophageal carcinoma (ESCA), GBM, KICH, acute myeloid leukemia (LAML), LGG, liver hepatocellular carcinoma (LIHC), LUAD, ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), PRAD, skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), THCA, and uterine carcinosarcoma (UCS), and was downregulated in CHOL, KIRC, KIRP, LUSC, and READ. Here, FDX1 is linked to prostate adenocarcinoma.